Alchemab Therapeutics
Last verified 2026-05-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $116.6Mattributed |
|---|---|
| Latest round | series-a, $27.0M, 2025-09-01attributed |
| Founded | 2019 |
| Headquarters | London |
| Industry | bio |
| Stage | series-a |
| Website | alchemab.com |
Alchemab develops antibody therapeutics by studying immune responses in disease-resistant individuals. It serves patients with hard-to-treat diseases through nature-inspired antibody discovery. Differentiator: adaptive immunity datasets fused with deep learning identify protective antibodies from resilient populations.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-09-01 | series-a | $27.0M | undisclosed |
Detected tech stack
Nginx, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, DoubleClick Floodlight, WordPress, WordPress Block Editor, WP Engine, PHP, MySQL, jquery 3.
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $27.0M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $116.6M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | alchemab.com, read 2026-05-16 |
| Description | self-reported | alchemab.com, read 2026-05-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.